159 related articles for article (PubMed ID: 38254721)
1. Reduced form of Galectin-1 Suppresses Osteoclastic Differentiation of Human Peripheral Blood Mononuclear Cells and Murine RAW264 Cells In Vitro.
Takeuchi T; Oyama M; Tamura M; Arata Y; Hatanaka T
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254721
[TBL] [Abstract][Full Text] [Related]
2. Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption.
Kogawa M; Findlay DM; Anderson PH; Ormsby R; Vincent C; Morris HA; Atkins GJ
Endocrinology; 2010 Oct; 151(10):4613-25. PubMed ID: 20739402
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. Peroxidase enzymes inhibit osteoclast differentiation and bone resorption.
Panagopoulos V; Liapis V; Zinonos I; Hay S; Leach DA; Ingman W; DeNichilo MO; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
Mol Cell Endocrinol; 2017 Jan; 440():8-15. PubMed ID: 27836774
[TBL] [Abstract][Full Text] [Related]
5. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
[TBL] [Abstract][Full Text] [Related]
6. Aminothiazoles inhibit osteoclastogenesis and PGE
Kats A; Gerasimcik N; Näreoja T; Nederberg J; Grenlöv S; Lagnöhed E; Desai S; Andersson G; Yucel-Lindberg T
J Cell Mol Med; 2019 Feb; 23(2):1152-1163. PubMed ID: 30506812
[TBL] [Abstract][Full Text] [Related]
7. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
8. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
[TBL] [Abstract][Full Text] [Related]
9. Osteostatin Inhibits M-CSF+RANKL-Induced Human Osteoclast Differentiation by Modulating NFATc1.
Ibáñez L; Nácher-Juan J; Terencio MC; Ferrándiz ML; Alcaraz MJ
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955685
[TBL] [Abstract][Full Text] [Related]
10. Downregulated fat mass and obesity-associated protein inhibits bone resorption and osteoclastogenesis by nuclear factor-kappa B inactivation.
Zhuang J; Ning H; Wang M; Zhao W; Jing Y; Liu X; Zu J; Kong P; Wang X; Sun C; Yan J
Cell Signal; 2021 Nov; 87():110137. PubMed ID: 34469786
[TBL] [Abstract][Full Text] [Related]
11. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.
Hyeon S; Lee H; Yang Y; Jeong W
Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472
[TBL] [Abstract][Full Text] [Related]
12. Ferryl Hemoglobin Inhibits Osteoclastic Differentiation of Macrophages in Hemorrhaged Atherosclerotic Plaques.
Zavaczki E; Gáll T; Zarjou A; Hendrik Z; Potor L; Tóth CZ; Méhes G; Gyetvai Á; Agarwal A; Balla G; Balla J
Oxid Med Cell Longev; 2020; 2020():3721383. PubMed ID: 32184915
[TBL] [Abstract][Full Text] [Related]
13. Galectin-3 Contributes to the Inhibitory Effect of lα,25-(OH)
Gu J; Zhang X; Zhang C; Li Y; Bian J; Liu X; Yuan Y; Zou H; Tong X; Liu Z
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948130
[TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion.
Okayasu M; Nakayachi M; Hayashida C; Ito J; Kaneda T; Masuhara M; Suda N; Sato T; Hakeda Y
J Biol Chem; 2012 Jun; 287(23):19229-41. PubMed ID: 22500026
[TBL] [Abstract][Full Text] [Related]
15. Deficiency in the phosphatase PHLPP1 suppresses osteoclast-mediated bone resorption and enhances bone formation in mice.
Mattson AM; Begun DL; Molstad DHH; Meyer MA; Oursler MJ; Westendorf JJ; Bradley EW
J Biol Chem; 2019 Aug; 294(31):11772-11784. PubMed ID: 31189651
[TBL] [Abstract][Full Text] [Related]
16. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.
Matsuzaki K; Udagawa N; Takahashi N; Yamaguchi K; Yasuda H; Shima N; Morinaga T; Toyama Y; Yabe Y; Higashio K; Suda T
Biochem Biophys Res Commun; 1998 May; 246(1):199-204. PubMed ID: 9600092
[TBL] [Abstract][Full Text] [Related]
17. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL).
Ang ES; Zhang P; Steer JH; Tan JW; Yip K; Zheng MH; Joyce DA; Xu J
J Cell Physiol; 2007 Sep; 212(3):787-95. PubMed ID: 17477372
[TBL] [Abstract][Full Text] [Related]
18. Anethole inhibits RANKL-induced osteoclastogenesis by downregulating ERK/AKT signaling and prevents ovariectomy-induced bone loss in vivo.
Qu H; Zhang Y; He R; Lin N; Wang C
Int Immunopharmacol; 2021 Nov; 100():108113. PubMed ID: 34530203
[TBL] [Abstract][Full Text] [Related]
19. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
[TBL] [Abstract][Full Text] [Related]
20. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT
Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
